The study, led by Laurine Noblecourt, Amanda Wicki and Benoit Van den Eynde of the Van den Eynde laboratory, together with former senior immunologist Carol Leung, who is now Group Leader at the NDM Centre for Immuno-Oncology, is published in the current issue of Cancer Cell. The researchers describe how the combination of carboplatin and paclitaxel, a regimen widely known as CarboTaxol, as well as the drug cyclophosphamide, can function as adjuvants, meaning substances that boost the effectiveness of vaccines, in preclinical models of cancer. Critically, the team found that this therapeutic effect is further enhanced when the combined regimen is supplemented with anti-PD-1 immune checkpoint blockade, an immunotherapy that prevents T cell exhaustion and thereby intensifies the T cell assault on tumors. The finding suggests that a carefully orchestrated triple combination of chemotherapy, vaccine and checkpoint inhibitor could deliver far greater tumor control than any of the components alone.

Our studies demonstrate in preclinical models of cancer that, if correctly timed, the combination of these chemotherapies with a cancer vaccine can synergize with ICB to enhance tumor control and significantly extend survival, said Leung. This therapeutic effect stems from the direct modulation of key functional traits of CD8+ T cells by the chemotherapies, which enables a better response to subsequent vaccination and, possibly, to anti-PD-1 ICB as well. The statement captures the central surprise of the work: rather than merely avoiding damage to the immune system, the chemotherapies appear to actively reprogram T cells into a state that primes them for stronger responses down the line. This is a direct, cell-intrinsic effect, not simply an indirect consequence of killing tumor cells or depleting suppressive immune populations.

That is not to say the indirect mechanisms were unknown. Previous studies have shown that in some cancers, chemotherapies can support immune checkpoint blockade by depleting immune cells within tumors that suppress anti-cancer immune responses. Chemotherapies can also stimulate anti-tumor immunity in another way: when they kill cancer cells, they release a variety of cancer antigens into the open, exposing them to the immune system and potentially broadening the immune response. But how chemotherapies might affect vaccine-induced immune responses to tumors specifically had never been methodically examined until now. Most clinical trials evaluating cancer vaccines administer the experimental therapy alongside chemotherapy simply because chemo is the standard of care, Noblecourt explained. But they do so without reference to established evidence on how chemotherapies affect vaccine responses. In other words, the field has been combining two powerful tools in the dark, with no systematic understanding of whether the pairing helps, hurts, or does nothing at all.

To fill that gap, the Ludwig Oxford team tested the effects of a panel of chemotherapies on the efficacy of a cancer vaccine developed in the Van den Eynde laboratory. The vaccine targets the non-human analogue of a common cancer antigen identified and characterized by Ludwig researchers, and it is delivered in two shots given days apart, a schedule immunologists call the prime and boost doses. The prime dose initiates the immune response, coaxing naive T cells into an activated state, while the boost dose expands and refines that response, driving the production of a larger and more potent army of antigen-specific T cells. Against this backdrop, the researchers administered various chemotherapy agents and measured how the resulting T cell populations and tumor outcomes changed across several preclinical cancer models.

The results were striking. CarboTaxol improved the efficacy of the vaccine when it was given with either the prime or the boost dose. Chemotherapies enhanced vaccine-induced CD8+ T cell responses against the targeted cancer antigen, expanded the pool of tumor-targeting CD8+ T cells and extended survival in preclinical models, said Noblecourt. This effect was further enhanced by ICB. Yet the experiments also revealed that timing was everything. The adjuvant effect of CarboTaxol was only seen when it was administered on the same day as the vaccine, and it was lost entirely if the chemotherapy and the vaccine were administered days apart. This temporal sensitivity is a detail with enormous clinical consequences, because it implies that trials which casually pair vaccines with standard chemotherapy schedules may be squandering a substantial therapeutic opportunity, or even undermining their own results, without ever knowing it.

Mechanistically, the researchers traced the effect to a specific population of CD8+ T cells that express a transcription factor known as TCF1. A master regulator of gene expression, TCF1 switches on genes that rejuvenate CD8+ T cells, extending their lifespan, their functionality and their ability to establish an immunological memory of an encountered antigen. In the hierarchy of anti-tumor immunity, TCF1-positive T cells occupy a privileged position. They behave somewhat like stem cells of the immune response, self-renewing and continuously feeding the front line with fresh effector cells that do the actual work of killing tumor cells. CD8+ T cells that express TCF1 are of critical importance to initiating and sustaining anti-cancer immune responses, said Wicki. The expansion of these cells by chemotherapy occurred independently of vaccination and established a deep pool of T cells for mobilization upon subsequent exposure to the vaccine antigen. The chemotherapy, in effect, digs a reservoir that the vaccine later draws upon.

Importantly, the team did not leave the finding confined to the laboratory. In support of the clinical relevance of their results, the researchers showed that the expansion of TCF1-positive CD8+ T cells could also be observed in samples taken from two independent cohorts of patients with different types of cancer who had been treated with CarboTaxol. This translational evidence matters because preclinical immunology has a long history of effects that fail to survive contact with human biology. Seeing the same cellular signature in patient samples treated with a standard-of-care regimen suggests that the mechanism operates in real clinical settings, and that the timing strategy validated in mice could plausibly be translated into trial design for human patients without requiring entirely new drugs.

Our findings have significant implications for clinical trials of cancer vaccines, said Van den Eynde. Current studies may not be taking advantage of a potential adjuvant effect that might be obtained by simply altering the timing of vaccination relative to chemotherapy. Our study paves the way to defining the optimal interval to induce such synergies. Further, because TCF1-positive CD8+ T cells are important for optimal responses to ICB as well, the mechanism we have identified here may extend beyond vaccines to other immunotherapy combinations. At the very least, our findings support the clinical evaluation of the combination of cancer vaccine, chemotherapy and anti-PD-1 checkpoint blockade examined in this study. The implication is remarkable in its economy: no new drug, no new target and no new manufacturing pipeline would be required, only a rational rescheduling of therapies that already exist and are already approved.

The study was supported by the Ludwig Institute for Cancer Research, the Berrow Foundation, the Swiss National Science Foundation and the Academy of Medical Sciences in the U.K. Beyond its immediate findings, the work reframes how the field should think about the interaction between cytotoxic therapy and immunotherapy. Rather than viewing chemotherapy as a necessary evil to be tolerated while the immune system is engaged, oncologists may come to see it as an active partner whose schedule, dose and pairing can be engineered to build, rather than burn, the anti-tumor immune response. If the same-day synergy and the TCF1-driven expansion hold up in clinical evaluation, the humble chemotherapy infusion could find an unexpected second career as one of the most powerful vaccine boosters in the oncology arsenal.

Subject of Research: How chemotherapy timing enhances CD8+ T cell responses and boosts cancer vaccine efficacy

Article Title: Chemo as a booster of cancer vaccines

Article References: Chemo as a booster of cancer vaccines. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cancer vaccines, chemotherapy, CarboTaxol, CD8+ T cells, TCF1, immune checkpoint blockade, anti-PD-1, adjuvants, immunotherapy, Ludwig Institute for Cancer Research, Cancer Cell, tumor immunology

Immunotherapy, often considered revolutionary in the fight against cancer, utilizes the body’s immune system to combat malignant cells. However, its efficacy can differ significantly among individuals and across various cancer types. Understanding the biological underpinnings that contribute to these discrepancies is critical, and the Weill Cancer Hub East aims to answer pressing questions regarding how nutrition and metabolism influence cancer immunotherapy outcomes. By engaging world-class experts and leveraging complementary strengths among partner institutions, the hub seeks to unlock new therapeutic possibilities that could lead to improved patient responses to this promising form of treatment.

Over the next decade, the research teams within the Weill Cancer Hub East plan to delve deeply into the associations between solid tumors and their surrounding environments, emphasizing the role of dietary factors and gut microbiota. The interplay of these elements is anticipated to provide insights into how they affect the efficacy of immunotherapy and overall cancer progression. The hub is not only focused on understanding these relationships but also explores emerging therapeutic avenues, such as GLP-1 agonists, which may simultaneously address issues related to metabolism and cancer treatment.

Sandy Weill, the founder of the Weill Family Foundation, expressed immense enthusiasm regarding the establishment of this hub, highlighting its potential to revolutionize cancer treatment. The Weills’ lasting commitment to enhancing scientific research and medical innovation signifies their belief in the importance of philanthropy in driving transformative progress. With a significant investment from the Weill Family Foundation and additional commitments from each of the participating institutions, the Weill Cancer Hub East is poised to become a leader in cancer research and an incubator for new ideas and innovations.

This initiative emerges at a time when the importance of interdisciplinary collaboration in science is increasingly recognized. By combining diverse perspectives and areas of expertise, the hub can inspire unprecedented scientific breakthroughs that would be difficult to achieve in isolated research environments. The framework encourages a holistic understanding of cancer, integrating knowledge from cancer biology, nutrition, immunology, and clinical trials. This comprehensive approach could yield novel insights into the means of optimizing immunotherapy for a broader range of patients suffering from various forms of cancer.

As the research progresses, the hub will implement seed funding programs aimed at incentivizing collaborative projects among scientists from the participating institutions. This funding strategy is designed to encourage innovative exploration of how tumors interact with their local environments, investigating possibilities for reprogramming tumor microenvironments and optimizing cellular functions by modifying patient metabolism and microbiota composition. These studies are especially essential in the context of personalized medicine, where treatment efficacy can significantly vary based on individual patient characteristics.

The potential implications of this collaborative effort extend beyond cancer treatment. Findings related to nutrition and metabolism could have broader consequences, informing approaches to metabolic disorders, cardiovascular diseases, and autoimmune conditions. By examining systemic connections between metabolism, diet, and immune response, researchers may uncover therapeutic strategies that enhance not only cancer treatment but also overall health and wellness for patients facing various medical challenges.

The hub’s leadership includes a scientific steering committee made up of leaders from each involved institution. These esteemed scientists are selecting and overseeing promising research projects that align with the objectives of the Weill Cancer Hub East. Their collective experience and insight are invaluable assets as the hub endeavors to set a new benchmark of excellence in cancer research, emphasizing the importance of cross-disciplinary collaboration and shared knowledge in advancing the field.

With facilities and laboratories situated across various top-tier institutions, the Weill Cancer Hub East is well-positioned to draw from an extensive pool of resources and talent. The integration of advanced research techniques such as metabolomics, computational analysis, and artificial intelligence into ongoing studies promises to elevate the quality of research outcomes and propel significant advancements in patient care and treatment options.

Additionally, the hub recognizes its obligation to train the next generation of cancer researchers and foster a vibrant scientific community. This initiative aims to maintain a flexible structure, allowing it to adapt to evolving research priorities and unexpected discoveries in the ever-changing landscape of cancer research. Fostered through symposia, workshops, and retreats, this focus not only cultivates talent but also inspires collaboration across various levels of expertise.

In summary, the Weill Cancer Hub East symbolizes a hopeful frontier in cancer research, uniting leading institutions and innovators with a shared vision of transforming cancer treatment through interdisciplinary collaboration. As the project moves forward, the potential for unprecedented breakthroughs and improved patient care serves as a constant reminder of the vital role that collaboration and investment in scientific research play in battling one of the most challenging health crises of our time. The collaboration aims to not only increase the effectiveness of immunotherapy but also contribute broadly to the biomedical landscape, ultimately improving the quality of life for countless patients battling cancer.

Subject of Research: The interplay between nutrition, metabolism, and cancer immunotherapy
Article Title: Weill Cancer Hub East: A New Dawn in Cancer Research and Treatment
News Publication Date: March 27, 2025
Web References: Princeton University, The Rockefeller University, Weill Cornell Medicine, Ludwig Institute for Cancer Research
References: N/A
Image Credits: Credit: John Abbott
Keywords: Cancer research, immunotherapy, nutrition, metabolism, multidisciplinary collaboration, Weill Cancer Hub East, GLP-1 agonists, personalized medicine, scientific innovation, cancer treatment, biomedical research.

Douglas Hanahan’s illustrious career is punctuated by groundbreaking discoveries that have forever altered the landscape of cancer biology. Currently serving as the Ludwig Distinguished Scholar at the Lausanne Branch of the Ludwig Institute for Cancer Research, Hanahan’s contributions have been vital in characterizing cancer’s multifaceted nature. Renowned for his work on innovative mouse models, he has elucidated the complex mechanisms underpinning tumorigenesis, revealing that the emergence of cancerous growth is a multistep process involving both genetic and environmental factors. This foundational understanding has not only advanced scientific discourse but has also laid the groundwork for more targeted therapeutic interventions.

At the heart of Hanahan’s discoveries is the recognition that cancer does not arise in isolation. Instead, he has articulated the critical role of the tumor microenvironment, emphasizing that malignant traits result from intricate interactions between cancer cells and various host cells. His collaboration with fellow scientist Robert A. Weinberg, PhD, on the seminal concept of the "Hallmarks of Cancer" serves as a cornerstone for contemporary cancer research, encapsulating the myriad ways through which cancers exploit cellular pathways to proliferate. This model has resonated across the research community, providing a vital framework for understanding the complex biology of cancers and inspiring a multitude of subsequent studies.

An integral part of Hanahan’s contributions is his exploration of the tumor microenvironment as a significant barrier to effective treatments. He was among the first to elucidate how an immune response, instead of solely targeting tumor cells, can be co-opted by malignancies to promote their own growth and evade therapeutic camps. This insight is invaluable for cancer immunotherapy, as understanding the immunosuppressive tactics employed by tumors can lead to more effective treatment strategies. His pioneering work has shaped current therapeutic approaches, bringing to light the need for therapies that not only target cancer cells directly but also address the supportive cellular ecosystem that aids tumor progression.

Significantly, Hanahan’s collaboration with the late Judah Folkman, MD, led to the discovery of the "angiogenic switch," a pivotal mechanism in tumor vascularization. The angiogenic switch describes how tumors hijack the body’s blood supply by promoting the growth of new blood vessels, thereby ensuring that their metabolic needs are met. This discovery has had profound implications for anti-cancer therapies, including the development of angiogenesis inhibitors aimed at starving tumors of their oxygen and nutrient supply. Hanahan’s work in this area exemplifies the interconnected nature of cancer biology, where understanding one aspect can lead to comprehensive treatment paradigms.

Moreover, Hanahan’s recent investigations delve into the intersection of cancer and neuroscience. His explorations into the role of neuronal signaling pathways in cancer cell behavior—such as invasion, metastasis, and immune evasion—signal a revolutionary frontier in cancer research. The implications of this work suggest that therapies might benefit from integrating neurobiology with oncology, potentially leading to novel treatment strategies that consider the tumor’s neurological interactions. This cross-disciplinary approach is reflective of the kind of innovative thinking that has characterized Hanahan’s career, bridging previously siloed areas of research to uncover new therapeutic targets.

The award lecture by Hanahan at the AACR Annual Meeting 2025 promises to be a highlight of the event, wherein he is expected to delve into his findings and the evolving landscape of cancer research. AACR’s Chief Executive Officer, Margaret Foti, PhD, MD (hc), has underscored the significance of Hanahan’s contributions, praising his interdisciplinary innovations that have significantly advanced the field of cancer biology. Foti acknowledges that Hanahan’s research has pivotal implications for clinical practice, enhancing the prospects of combating cancer effectively and improving patient outcomes.

The Pezcoller Foundation, in its collaboration with the AACR, aims to celebrate the achievements of scientists who have made transformative contributions to cancer research. Enzo Galligioni, MD, president of the Pezcoller Foundation, articulated the joy of honoring Hanahan this year, particularly given the impactful nature of his discoveries which have shaped the research agenda for countless scientists. This recognition not only emphasizes individual excellence but also reflects the foundation’s commitment to fostering scientific innovation in the fight against cancer.

As an esteemed member of the AACR since 2000 and a Fellow of the AACR Academy since 2014, Hanahan’s reputation within the scientific community is unmatched. His accolades—including the AACR Lifetime Achievement Award and the National Cancer Association of France Grand Prize for Biology—testify to his significant contributions over an extensive career spanning decades. His membership in distinguished organizations such as the Royal Society and the National Academy of Sciences further cements his legacy as a cornerstone of modern cancer research.

With an educational background in physics from the Massachusetts Institute of Technology and a PhD in biophysics from Harvard University, Hanahan’s academic prowess provides a remarkable foundation for his innovative research in cancer biology. His multifaceted background equips him with a unique perspective, allowing for the investigation of cancer through the lens of emergent technologies and interdisciplinary methodologies.

In conclusion, the Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research not only recognizes Douglas Hanahan’s remarkable scientific contributions but also showcases the collaborative spirit of the global cancer research community. As we look forward to the AACR Annual Meeting 2025, the anticipation for Hanahan’s award lecture and subsequent discussions surrounding his work marks a significant moment in the continued journey towards understanding and effectively combating cancer. His trailblazing efforts inspire not only the current generation of cancer researchers but also lay the groundwork for future innovations that will undoubtedly emerge in the quest for cures.

Subject of Research: Multistep tumorigenesis, tumor microenvironment, angiogenesis in cancer, cancer neuroscience.

Article Title: Douglas Hanahan: A Pioneer in Cancer Research Honored with Pezcoller Foundation-AACR Award.

News Publication Date: [Date not specified in the original content]

Web References: https://www.pezcoller.it/en/, https://www.aacr.org/, https://www.aacr.org/meeting/aacr-annual-meeting-2025/, https://www.aacr.org/professionals/research/scientific-achievement-awards-and-lectureships/scientific-award-recipients/pezcoller-aacr-international-award-recipients/, https://www.aacr.org/professionals/membership/aacr-academy/fellows/douglas-hanahan-phd/

References: [Specific references not included in the original content]

Image Credits: [Image credits not specified in the original content]

Keywords: Cancer research, Douglas Hanahan, Pezcoller Foundation, AACR, tumor microenvironment, angiogenesis, cancer immunotherapy, neuroscience.